Dr. Brandon Lennep, MD
NPI: 1073953147
Total Payments
$22,542
2024 Payments
$378.62
Companies
30
Transactions
364
Medicare Patients
1,791
Medicare Billing
$178,496
Payment Breakdown by Category
Other$8,860 (39.3%)
Food & Beverage$7,816 (34.7%)
Travel$5,125 (22.7%)
Education$540.94 (2.4%)
Consulting$200.00 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,816 | 344 | 34.7% |
| Honoraria | $5,160 | 1 | 22.9% |
| Travel and Lodging | $5,125 | 12 | 22.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,700 | 1 | 16.4% |
| Education | $540.94 | 5 | 2.4% |
| Consulting Fee | $200.00 | 1 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $11,045 | 65 | $0 (2023) |
| Medtronic Vascular, Inc. | $2,881 | 13 | $0 (2019) |
| Abbott Laboratories | $2,091 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,033 | 16 | $0 (2024) |
| ABIOMED | $681.75 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $430.00 | 26 | $0 (2024) |
| Astellas Pharma US Inc | $428.18 | 22 | $0 (2020) |
| Bayer Healthcare Pharmaceuticals Inc. | $396.62 | 13 | $0 (2024) |
| Amgen Inc. | $368.24 | 27 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $341.71 | 11 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $378.62 | 21 | Merck Sharp & Dohme LLC ($80.33) |
| 2023 | $4,445 | 32 | PFIZER INC. ($3,809) |
| 2022 | $7,339 | 45 | PFIZER INC. ($6,556) |
| 2021 | $696.85 | 30 | Boehringer Ingelheim Pharmaceuticals, Inc. ($210.11) |
| 2020 | $562.74 | 24 | Abbott Laboratories ($252.77) |
| 2019 | $5,851 | 87 | Medtronic Vascular, Inc. ($2,881) |
| 2018 | $2,007 | 73 | Merck Sharp & Dohme Corporation ($830.80) |
| 2017 | $1,262 | 52 | AstraZeneca Pharmaceuticals LP ($237.81) |
All Payment Transactions
364 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $21.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/03/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $16.06 | General |
| Category: Medical Device | ||||||
| 11/12/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 11/05/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $16.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/11/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Heart Failure | ||||||
| 06/29/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Cardiology | ||||||
| 05/01/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Cardiology | ||||||
| 04/30/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN | Food and Beverage | In-kind items and services | $20.14 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 04/26/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: Cardiology | ||||||
| 04/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.52 | General |
| Category: Cardiovascular | ||||||
| 04/16/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/04/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/26/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.85 | General |
| Category: Cardiovascular | ||||||
| 03/19/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 03/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Cardio-pulmonary | ||||||
| 02/20/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/16/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.33 | General |
| Category: Cardiovascular | ||||||
| 01/26/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.49 | General |
| Category: Cardiovascular | ||||||
| 11/15/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/28/2023 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Cardio-pulmonary | ||||||
| 10/20/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 407 | 614 | $165,173 | $48,836 |
| 2022 | 15 | 683 | 1,063 | $199,394 | $61,111 |
| 2021 | 12 | 609 | 902 | $161,832 | $54,903 |
| 2020 | 3 | 92 | 162 | $36,295 | $13,646 |
Total Patients
1,791
Total Services
2,741
Medicare Billing
$178,496
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 140 | $40,740 | $12,054 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 72 | 86 | $31,648 | $10,230 | 32.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 18 | 60 | $32,220 | $9,130 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 91 | $22,477 | $7,283 | 32.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 30 | 32 | $13,568 | $4,110 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $5,568 | $1,691 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 26 | $4,394 | $1,352 | 30.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,446 | $1,196 | 26.9% |
| 93798 | Outpatient heart rehabilitation with electrocardiogram (ecg) monitoring, quality health care professional services | Office | 2023 | 35 | 78 | $3,198 | $766.08 | 24.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 14 | 14 | $3,976 | $663.78 | 16.7% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 35 | 39 | $1,092 | $212.10 | 19.4% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Facility | 2023 | 11 | 11 | $1,026 | $123.30 | 12.0% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 12 | 12 | $820.00 | $25.41 | 3.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 23 | 94 | $50,478 | $15,318 | 30.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 41 | 161 | $37,772 | $12,269 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 80 | 94 | $30,476 | $11,857 | 38.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 97 | $21,374 | $7,728 | 36.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 29 | $13,474 | $4,263 | 31.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 268 | 335 | $8,354 | $1,896 | 22.7% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2022 | 19 | 19 | $10,032 | $1,834 | 18.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $4,586 | $1,588 | 34.6% |
| 93798 | Outpatient heart rehabilitation with electrocardiogram (ecg) monitoring, quality health care professional services | Office | 2022 | 40 | 128 | $5,248 | $1,306 | 24.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 24 | 24 | $7,203 | $1,264 | 17.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 16 | $3,968 | $1,240 | 31.2% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 12 | 12 | $1,344 | $226.70 | 16.9% |
About Dr. Brandon Lennep, MD
Dr. Brandon Lennep, MD is a Advanced Heart Failure and Transplant Cardiology healthcare provider based in Jackson, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2013. The National Provider Identifier (NPI) number assigned to this provider is 1073953147.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brandon Lennep, MD has received a total of $22,542 in payments from pharmaceutical and medical device companies, with $378.62 received in 2024. These payments were reported across 364 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($7,816).
As a Medicare-enrolled provider, Lennep has provided services to 1,791 Medicare beneficiaries, totaling 2,741 services with total Medicare billing of $178,496. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Advanced Heart Failure and Transplant Cardiology
- Location Jackson, MS
- Active Since 07/03/2013
- Last Updated 08/16/2024
- Taxonomy Code 207RA0001X
- Entity Type Individual
- NPI Number 1073953147
Products in Payments
- ORGOVYX (Drug) $6,486
- XTANDI (Drug) $3,700
- CardioMEMS HF System (Device) $1,373
- MK-1242 (Drug) $830.80
- Impella (Device) $681.75
- HeartMate 3 Left Ventricular Dev (Device) $480.89
- CHANTIX (Drug) $410.43
- ELIQUIS (Drug) $364.19
- Adempas (Drug) $354.03
- ENTRESTO (Drug) $330.32
- XARELTO (Drug) $323.83
- JARDIANCE (Drug) $323.07
- LEXISCAN (Drug) $267.24
- LifeVest (Device) $255.62
- Corlanor (Drug) $223.23
- ORENITRAM (Drug) $207.96
- VYNDAQEL (Drug) $203.86
- VERQUVO (Drug) $202.63
- Definity (Drug) $185.25
- UPTRAVI (Drug) $183.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.